Fig 1: Effect of iASPP knockdown and overexpression on colony formation(A) Pictures of colony formation assay in MUG-Chor1 and U-CH1 cells after the iASPP knockdown with iASPP-shRNAs. (B) The number of colonies in both cells after the iASPP knockdown with iASPP-shRNAs. (C) Pictures of colony formation assay in MUG-Chor1 and U-CH1 cells after the iASPP overexpression with EGFP-iASPP. (D) The number of colonies in both cells after the iASPP overexpression with EGFP-iASPP. n = 3. Mean ± SEM. *p < 0.01, ***p < 0.001, iASPP-shRNA1 group or iASPP-shRNA2 group vs. shRNA-CON group, and EGFP-iASPP group vs. EGFP-CON group. CON: control.
Fig 2: Effect of iASPP knockdown and overexpression on cells invasion(A) Pictures of transwell invasion assays in MUG-Chor1 and U-CH1 cells after the iASPP knockdown with iASPP-shRNAs. (B) The number of both cells that invaded the substratum of the membrane per view under a 100× magnification after the iASPP knockdown with iASPP-shRNAs. (C) Pictures of transwell invasion assays in MUG-Chor1 and U-CH1 cells after the iASPP overexpression with EGFP-iASPP. (D) The number of both cells that invaded the substratum of the membrane per view under a 100× magnification after the iASPP overexpression with EGFP-iASPP. n = 3. Mean ± SEM. *p < 0.05, *p < 0.01, ***p < 0.001, iASPP-shRNA1 group or iASPP-shRNA2 group vs. shRNA-CON group, and EGFP-iASPP group vs. EGFP-CON group. CON: control. Bar scale = 100 μm.
Fig 3: Effect of iASPP knockdown on cells apoptosis after cisplatin treatment(A) Pictures of cells apoptosis detected by flow cytometry in 20 μM cisplatin-treated MUG-Chor1 and U-CH1 cells after the iASPP knockdown with iASPP-shRNAs. (B) The results of statistical analysis of total apoptosis rate in 20 μM cisplatin-treated cells after the iASPP knockdown with iASPP-shRNAs. n = 3. Mean ± SEM. *p < 0.05, ***p < 0.001, iASPP-shRNA1 group or iASPP-shRNA2 group vs. shRNA-CON group. CON: control.
Fig 4: Verification of the interaction between CDK1 and iASPP proteins (A) GST pull-down assays showing GST-CKD1 pulled down His-iASPP. (B) Confirmation of the interaction between CDK1 and iASPP using Co-IP assays. (C) The binding structure schematic diagram showing two possible interacting regions of CDK1 protein and iASPP protein, generated using PyMol.
Fig 5: Expression levels of CDK1 and iASPP and their correlation in CRC tissues (A) and (B) The expression levels of CDK1 and iASPP mRNA in CRC tissues derived from patients in different stages were deteremined by using real-time PCR assays, compared to normal tissues. The data are presented as mean ± SD of three independent experiments. *P < 0.05, **P < 0.01. (C) The protein levels of CDK1 and iASPP in tumor tissues and adjacent normal tissues (normal tissues N1/2, N3 and N4; tumor tissues P1/2, P3 and P4) were determined using Western blot assays. (D) and (E) Expression of CDK1 and iASPP mRNA in 43 pairs of CRC tissues and their corresponding adjacent non-tumorous tissues (ANTs) in a training cohort. Expression level of CDK1 and iASPP mRNA was determined by real-time PCR and normalized to U6. Fold change were analyzed using the formula 2−(ΔΔCT [CRC/ ANT]). Red line indicates fold change of CDK1 or iASPP mRNA equal to 2. (F) The Spearman's rank correlation analysis was performed to analyze the correlation between CDK1 and iASPP mRNA in CRC tissues. (G) Data from Cytoscape showing the candidate proteins which could interact with iASPP protein.
Supplier Page from Abcam for Anti-iASPP antibody